We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Sally
Eldeghaidy
sally.eldeghaidy@nottingham.ac.uk
Kyaw Linn
Su Khin
k.sukhin@nhs.net
Diabetes mellitus
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
A limited number of studies have reported that sweet taste sensation is reduced in individuals with T2D. In the proposed research,we will expand on previous work and further assess whether abnormalities in oral sweet sensitivity affects people with prediabetes. We will also study whether oral sweet sensitivity is related to an individual’s sweet preference and daily sugar intake,and how this is changed by diabetes status. Previous studies,including work from our group,have looked at brain responses to oral sweet perception in individuals without T2D or prediabetes via fMRI,however no study has yet looked at this in the context of prediabetes or T2D. Gut sweet sensing showed to be defective in individuals with T2D,and links to faster glucose absorption and higher blood glucose levels. However,previous studies have not looked at the relationship between gut and brain responses to reflect on how information from the gut sweet sensing is translated to the brain. This proposal will build on our past research and unique expertise to bring together oral,gut and brain sweet sensing to assess the impact of any changes in people with prediabetes or T2D that may increase risk or worsen the disease.
Habitual high consumption of added sugars increases the risk of developing,or worsening,type 2 diabetes (T2D). Despite this,individuals with T2D have told us that craving and consuming excess sugar is a common and distressing problem to balance. A better understanding of the mechanisms that govern sugar taste and reward,as well as taste control of blood sugar by the gut,is crucial to prevent and better treat T2D. Unfortunately,our current understanding of how sweet is detected by the tongue and in the gut and then conveyed to the central nervous system is limited. The present study will use a sophisticated brain imaging technique,called functional magnetic resonance imaging (fMRI) to identify how sweet sensing is communicated from the tongue and gut to the brain in individuals with and without T2D or prediabetes. Understanding these mechanisms will enable personalised treatments to be developed that preserve taste reward,but which target sweet sensing to optimise control of blood sugar in prediabetes and T2D. Our study will also empower individuals with prediabetes or T2D to adhere to dietary plans,to reduce the incidence and burden of T2D.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Phase 1 Exclusion criteria: 1. Current pregnancy or breastfeeding 2. Current treatment with insulin or any other diabetic medications apart from metformin 3. History of neurological,gastrointestinal injury or disease 4. Any medication that is known to alter taste perception 5. Smokers 6. allergy to sugar,sucralose,quinine,citric acid,monosodium glutamate,sodium chloride Phase 2 and 3 Exclusion Criteria: 1. individuals with Neurological or gastrointestinal disorders (IBD/ IBS) 2. those who have contraindications to MRI including metal implants 3. those who are unable to lie flat 4. smokers 5. those who have taken part in research projects within the last 3 months (projects involving administering a drug,invasive procedure i.e. venepuncture >50 ml,endoscopy,or exposure to ionising radiation)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Nottingham and funded by THE BRITISH DIABETIC ASSOCIATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 63488
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
